	US 12,246,067 B2
	Neoantigens and uses thereof
Vikram Juneja, Waltham, MA (US)
Assigned to BioNTech US Inc., Cambridge, MA (US)
Appl. No. 17/254,128
Filed by BioNTech US Inc., Cambridge, MA (US)
PCT Filed Jun. 19, 2019, PCT No. PCT/US2019/038019 § 371(c)(1), (2) Date Dec. 18, 2020, PCT Pub. No. WO2019/246286, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/800,735, filed on Feb. 4, 2019.
Claims priority of provisional application 62/687,188, filed on Jun. 19, 2018.
Prior Publication US 2021/0268091 A1, Sep. 2, 2021
Int. Cl. A61K 47/20 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); C07K 14/62 (2006.01); C12N 5/0783 (2010.01)

CPC A61K 47/20 (2013.01) [A61K 39/001164 (2018.08); A61K 39/4611 (2023.05); A61K 39/4632 (2023.05); A61K 39/464401 (2023.05); A61K 39/464464 (2023.05); A61K 45/06 (2013.01); A61K 47/26 (2013.01); C07K 14/62 (2013.01); C12N 5/0638 (2013.01); A61K 38/00 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/575 (2013.01); A61K 2039/645 (2013.01)]

19 Claims

1. A composition comprising T cells specific to an HLA-peptide complex comprising at least one mutant RAS peptide sequence, wherein the HLA-peptide complex comprises a protein encoded by an HLA-C03:04 allele, and the at least one mutant RAS peptide sequence consists of

	(SEQ ID NO: 2064)
	GAVGVGKSA.